[Onchodermatitis (sowda) in patients in Yémen. Clinical and histologic course after treatment with ivermectin].
Sowda skin lesions are of medical and social importance in Yemen. Ivermectin (Mectizan) chose as a control strategy plan in onchocerciasis is active during 3 months for the less on clinical and histological data. After a short increase of itching and oedematous skin aspects clinical signs decrease. Some patients notice an itching rebound after 90 days. Histologically, localized ingratiates, presence of mononuclear cells and melenin loaded histiocytes and eosinophils decreased. The rythm cure has to be studied on a longer period but 3 to 6 months repetition between oral treatment with 200 micrograms/kg dose during two years could be effective.
al Qubati
Y
Y
Programme national de lutte contre la lèpre, Taiz, République du Yémen.
Reynouard
F
F
Kumar
F
F
Gaxotte
P
P
Richard-Lenoble
D
D
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000969:Antinematodal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004334:Drug Administration Schedule; D004478:Ectoparasitic Infestations / Q000188:drug therapy* / Q000473:pathology; D004804:Eosinophils / Q000473:pathology; D005369:Filaricides / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006644:Histiocytes / Q000473:pathology; D006801:Humans; D007559:Ivermectin / Q000008:administration & dosage / Q000627:therapeutic use*; D007868:Leg Dermatoses / Q000188:drug therapy / Q000469:parasitology / Q000473:pathology; D007958:Leukocyte Count; D008214:Lymphocytes / Q000469:parasitology / Q000473:pathology; D008543:Melanins; D008875:Middle Aged; D009855:Onchocerciasis / Q000188:drug therapy* / Q000473:pathology; D010950:Plasma Cells / Q000469:parasitology / Q000473:pathology; D011537:Pruritus / Q000188:drug therapy / Q000469:parasitology / Q000473:pathology; D015006:Yemen
D000969:Antinematodal Agents; D005369:Filaricides; D008543:Melanins; D007559:Ivermectin
Onchodermatite (Sowda) chez des patients du Yémen. Evolution clinique et histologique après traitement par ivermectine.